The Rise Of Non-Viral Drug Delivery Systems Is Promoting Customized Medicines

The rising prevalence of chronic diseases and advancing nanotechnology research are fueling the growth of non-viral drug delivery systems. These novel systems offer advantages like enhanced efficacy, minimized toxicity and ease of large-scale production compared to viral vectors. Non-viral systems employ nanocarriers such as lipid-based vesicles, polymeric nanoparticles and inorganic particles to efficiently deliver therapeutic payloads like proteins, nucleic acids and small molecule drugs to target sites in the body. They play a vital role in revolutionizing disease treatment by facilitating development of precision and personalized medicines.

The Non-Viral Drug Delivery Systems Market is estimated to be valued at US$ 8.1 Bn in 2024 and is expected to exhibit a CAGR of 13% over the forecast period 2024-2031.

Continuous technological innovations are leading to development of novel nanocarrier formulations with improved biocompatibility and controlled release properties. Further, growing demand for targeted therapies in areas such as cancer and genetic disorders is fueling research into these systems.

Key Takeaways

Key players operating in the Non-Viral Drug Delivery Systems are Arcturus Therapeutics, Bio-Path Holdings, CureVac, Entos Pharmaceuticals, and eTheRNA Immunotherapies. These companies are investing in R&D to develop proprietary non-viral carriers and production processes.

Growing incidence of chronic ailments such as cardiovascular diseases, neurological disorders and cancer is a major factor driving demand for safer and more effective therapeutic options. Non-viral carriers address these needs by enabling targeted drug delivery and controlled release.

Several market players are expanding globally through strategic collaborations to broaden their product portfolios and market reach. For instance, Bio-Path has collaborated with Johnson & Johnson to develop liposomal technologies for cancer treatment.

Market Key Trends

Non-viral carriers are evolving from first generation “burst release” systems to second generation “sustained release” systems driven by advances in material science and engineering. Microsphere and nanoparticle formulations that minimize initial burst and prolong drug release over weeks are being investigated for chronic disease management.

Novel materials such as graphene and inorganic polymers are being explored as non-viral vectors due to properties like excellent biocompatibility, strong mechanical strength and ease of surface functionalization for targeted delivery. Carbon nanotubes loaded with chemotherapeutics show promise for cancer therapy.

Gene therapy is a major application area where non-viral delivery systems are playing a crucial role. Significant funding and clinical trials conducted worldwide on plasmid DNA, antisense oligonucleotides and mRNA therapeutics have accelerated the progress of gene-based drugs, positioning non-viral carriers for commercial success.

Porter’s Analysis

Threat of new entrants: Low barriers of entry in some segments but costly R&D for patented systems limits newcomers.

Bargaining power of buyers: Large buyers have bargaining power but they also seek innovative solutions provided by niche players.

Bargaining power of suppliers: Suppliers of raw materials have lower power as materials are commodity products available from multiple sources.

Threat of new substitutes: Potential for new substitutes from nanotechnology but existing means continue providing value for delivery also.

Competitive rivalry: Intense rivalry among multiple players continually developing novel approaches and drug-device combinations.

Geographical concentration of value is in North America and Europe due to presence of major pharmaceutical players and growing investment in R&D for advanced delivery platforms. Asia Pacific region is growing at the fastest pace led by China, India and other developing nations where chronic diseases are rising rapidly along with investments in healthcare sector.

What Are The Key Data Covered In This Non-Viral Drug Delivery Systems Market Report?

:- Market CAGR throughout the predicted period

:- Comprehensive information on the aspects that will drive the Non-Viral Drug Delivery Systems Market’s growth between 2024 and 2031.

:- Accurate calculation of the size of the Non-Viral Drug Delivery Systems Market and its contribution to the market, with emphasis on the parent market

:- Realistic forecasts of future trends and changes in consumer behaviour

:- Non-Viral Drug Delivery Systems Market Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa

:- A complete examination of the market’s competitive landscape, as well as extensive information on vendors

:- Detailed examination of the factors that will impede the expansion of Non-Viral Drug Delivery Systems Market vendors

FAQ’s

Q.1 What are the main factors influencing the Non-Viral Drug Delivery Systems Market?

Q.2 Which companies are the major sources in this industry?

Q.3 What are the market’s opportunities, risks, and general structure?

Q.4 Which of the top Non-Viral Drug Delivery Systems Market companies compare in terms of sales, revenue, and prices?

Q.5 Which businesses serve as the Non-Viral Drug Delivery Systems Market’s distributors, traders, and dealers?

Q.6 How are market types and applications and deals, revenue, and value explored?

Q.7 What does a business area’s assessment of agreements, income, and value implicate?

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it